Indication
Stage IVB Colon Cancer
7 clinical trials
9 products
1 drug
Clinical trial
A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
IpilimumabProduct
NivolumabDrug
RegorafenibClinical trial
Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)Status: Recruiting, Estimated PCD: 2025-01-31
Product
SX-682Clinical trial
Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain TumorsStatus: Completed, Estimated PCD: 2023-09-18
Product
18F-FMAUClinical trial
A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy DeliveryStatus: Recruiting, Estimated PCD: 2025-07-01
Product
NBT-NM108Clinical trial
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2021-07-31
Product
SavolitinibClinical trial
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
PanitumumabProduct
Trifluridine and TipiracilClinical trial
A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive TherapyStatus: Active (not recruiting), Estimated PCD: 2023-08-01
Product
M7824